These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 32333311)

  • 1. Identification of METTL3 as an Adverse Prognostic Biomarker in Hepatocellular Carcinoma.
    Liu GM; Zeng HD; Zhang CY; Xu JW
    Dig Dis Sci; 2021 Apr; 66(4):1110-1126. PubMed ID: 32333311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N6-methyladenosine methylation-related genes
    Wang Y; Li T; Liu H; Liang Y; Wang G; Fu G; Takatsuki M; Qu H; Jing F; Li J; Jiang M
    Ann Transl Med; 2022 Dec; 10(24):1398. PubMed ID: 36660669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple m
    Qu N; Qin S; Zhang X; Bo X; Liu Z; Tan C; Wen G; Jiang H
    BMC Cancer; 2020 Feb; 20(1):165. PubMed ID: 32111180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
    Jiang H; Ning G; Wang Y; Lv W
    Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HBXIP drives metabolic reprogramming in hepatocellular carcinoma cells via METTL3-mediated m6A modification of HIF-1α.
    Yang N; Wang T; Li Q; Han F; Wang Z; Zhu R; Zhou J
    J Cell Physiol; 2021 May; 236(5):3863-3880. PubMed ID: 33305825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cancer Genome Atlas (TCGA) based m
    Liu J; Sun G; Pan S; Qin M; Ouyang R; Li Z; Huang J
    Bioengineered; 2020 Dec; 11(1):759-768. PubMed ID: 32631107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of METTL3 and METTL14 in hepatocellular carcinoma.
    Liu X; Qin J; Gao T; Li C; Chen X; Zeng K; Xu M; He B; Pan B; Xu X; Pan Y; Sun H; Xu T; Wang S
    Aging (Albany NY); 2020 Nov; 12(21):21638-21659. PubMed ID: 33159022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
    Li L; Xie R; Lu G
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross talk between RNA N6-methyladenosine methyltransferase-like 3 and miR-186 regulates hepatoblastoma progression through Wnt/β-catenin signalling pathway.
    Cui X; Wang Z; Li J; Zhu J; Ren Z; Zhang D; Zhao W; Fan Y; Zhang D; Sun R
    Cell Prolif; 2020 Mar; 53(3):e12768. PubMed ID: 31967701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression profiles and prognostic significance of RNA N6-methyladenosine-related genes in patients with hepatocellular carcinoma: evidence from independent datasets.
    Zhou Y; Yin Z; Hou B; Yu M; Chen R; Jin H; Jian Z
    Cancer Manag Res; 2019; 11():3921-3931. PubMed ID: 31118805
    [No Abstract]   [Full Text] [Related]  

  • 11. Expression pattern and prognostic value of N6-methyladenosine RNA methylation key regulators in hepatocellular carcinoma.
    Deng M; Fang L; Li SH; Zhao RC; Mei J; Zou JW; Wei W; Guo RP
    Mutagenesis; 2021 Oct; 36(5):369-379. PubMed ID: 34467992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. m6A-Related Genes Contribute to Poor Prognosis of Hepatocellular Carcinoma.
    Zou Y; Jiang G; Xie Y; Li H
    Comput Math Methods Med; 2022; 2022():2427987. PubMed ID: 36339682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. METTL3 expression is associated with glycolysis metabolism and sensitivity to glycolytic stress in hepatocellular carcinoma.
    Lin Y; Wei X; Jian Z; Zhang X
    Cancer Med; 2020 Apr; 9(8):2859-2867. PubMed ID: 32068977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contributions and Prognostic Values of N6-Methyladenosine RNA Methylation Regulators in Hepatocellular Carcinoma.
    Qi LW; Jia JH; Jiang CH; Hu JM
    Front Genet; 2020; 11():614566. PubMed ID: 33519919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.
    Chen M; Wei L; Law CT; Tsang FH; Shen J; Cheng CL; Tsang LH; Ho DW; Chiu DK; Lee JM; Wong CC; Ng IO; Wong CM
    Hepatology; 2018 Jun; 67(6):2254-2270. PubMed ID: 29171881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of a disease-specific lncRNA-miRNA-mRNA regulatory network reveals potential regulatory axes and prognostic biomarkers for hepatocellular carcinoma.
    Zhang Q; Sun L; Zhang Q; Zhang W; Tian W; Liu M; Wang Y
    Cancer Med; 2020 Dec; 9(24):9219-9235. PubMed ID: 33232580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma.
    Yang K; Wang F; Li K; Peng G; Yang H; Xu H; Xiang Y; Sun H
    Technol Cancer Res Treat; 2022; 21():15330338221085354. PubMed ID: 35422168
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic Value of an m6A RNA Methylation Regulator-Based Signature in Patients with Hepatocellular Carcinoma.
    Wu X; Zhang X; Tao L; Dai X; Chen P
    Biomed Res Int; 2020; 2020():2053902. PubMed ID: 32733931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
    Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
    Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analyses of competing endogenous RNA networks reveal potential biomarkers for predicting hepatocellular carcinoma recurrence.
    Yan P; Huang Z; Mou T; Luo Y; Liu Y; Zhou B; Cao Z; Wu Z
    BMC Cancer; 2021 Apr; 21(1):436. PubMed ID: 33879119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.